You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雙鷺藥業(002038.SZ):參股公司首藥控股科創板IPO申請獲上交所受理
格隆匯 03-17 11:50

格隆匯3月17日丨雙鷺藥業(002038.SZ)宣佈,公司近日從參股公司首藥控股(北京)股份有限公司(簡稱“首藥控股”)處獲悉,首藥控股已於近日向上交所提交首次公開發行股票並在科創板上市的申請材料,並已取得了上交所於2021年3月16日出具的《關於受理首藥控股(北京)股份有限公司首次公開發行股票並在科創板上市申請的通知》(上證科審(受理)[2021]14號),上交所對首藥控股提交的首次公開發行股票並在科創板上市的申請材料予以受理。

首藥控股擬計劃發行3718萬股,發行後總股本約為1.49億股。公司目前持有首藥控股526.32萬股,佔首次公開發行前總股本的4.7187%,公司全資子公司北京雙鷺生物技術有限公司持有約110.11萬股,佔首次公開發行前總股本的0.9872%,合計持有首藥控股總股本的5.7059%。此外,北京崇德英盛創業投資有限公司(雙鷺藥業持有37.95%股權)持有首藥控股約44.04萬股,佔首次公開發行前總股本的0.3949%。

首藥控股是一家主要從事創新藥研發的高新技術企業,成立於2016年4月,北京賽林泰醫藥技術有限公司為其全資子公司。首藥控股目前所有產品均處於研究開發的I-III期臨牀和臨牀前階段,除有部分產品轉讓獲得收益外暫未有產品上市產生的銷售收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account